Technical Analysis for KPTI - Karyopharm Therapeutics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | -6.01% | |
| Volume Surge | Other | -6.01% |
| Alert | Time |
|---|---|
| Down 3% | about 5 hours ago |
| Down 2 % | about 5 hours ago |
| Down 1% | about 6 hours ago |
| Possible NR7 | about 6 hours ago |
| 1.5x Volume Pace | about 9 hours ago |
Get a Trading Sidekick!
- Earnings date: 07/31/2024
Karyopharm Therapeutics Inc. Description
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company's lead drug candidate includes Selinexor, an oral selective inhibitors of nuclear export (SINE) compound that specifically blocks XPO1 cargo binding is in Phase I clinical trials in patients with heavily pretreated relapsed and/or refractory hematological and solid tumor malignancies. Its other drug candidates comprise KPT-350 and related SINE compounds; PAK4 inhibitors; and Verdinexor, a SINE compound that is in Phase IIb clinical trials in pet dogs with newly-diagnosed or first relapse after chemotherapy lymphomas. The company was founded in 2008 and is based in Natick, Massachusetts.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Cancer Pharmaceutical Disease Treatment Of Cancer Oncology Lymphoma Chemotherapy Occupational Safety And Health Dog Stage Pharmaceutical Antibody Drug Conjugate
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.95 |
| 52 Week Low | 0.6174 |
| Average Volume | 1,504,516 |
| 200-Day Moving Average | 1.07 |
| 50-Day Moving Average | 1.04 |
| 20-Day Moving Average | 0.97 |
| 10-Day Moving Average | 0.97 |
| Average True Range | 0.09 |
| RSI (14) | 34.21 |
| ADX | 13.38 |
| +DI | 19.64 |
| -DI | 29.29 |
| Chandelier Exit (Long, 3 ATRs) | 0.89 |
| Chandelier Exit (Short, 3 ATRs) | 1.09 |
| Upper Bollinger Bands | 1.10 |
| Lower Bollinger Band | 0.85 |
| Percent B (%b) | -0.13 |
| BandWidth | 25.75 |
| MACD Line | -0.04 |
| MACD Signal Line | -0.03 |
| MACD Histogram | -0.009 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.96 | ||||
| Resistance 3 (R3) | 0.98 | 0.95 | 0.94 | ||
| Resistance 2 (R2) | 0.95 | 0.91 | 0.94 | 0.93 | |
| Resistance 1 (R1) | 0.88 | 0.89 | 0.86 | 0.86 | 0.92 |
| Pivot Point | 0.85 | 0.85 | 0.84 | 0.84 | 0.85 |
| Support 1 (S1) | 0.78 | 0.81 | 0.77 | 0.77 | 0.71 |
| Support 2 (S2) | 0.75 | 0.79 | 0.74 | 0.70 | |
| Support 3 (S3) | 0.68 | 0.75 | 0.69 | ||
| Support 4 (S4) | 0.67 |
